Key result
Elevated cholesterol is linked to ~58% higher cardiovascular disease risk.
Why the study?
How strongly is high cholesterol associated with cardiovascular and systemic outcomes, and what is the comparative effectiveness and bias profile of lipid-lowering interventions across published studies?
Meta-Analysis
How strongly is high cholesterol associated with cardiovascular and systemic outcomes, and what is the comparative effectiveness and bias profile of lipid-lowering interventions across published studies?
This large meta-research synthesis confirms the association between high cholesterol and cardiovascular disease and the potent LDL-lowering of PCSK9 inhibitors and inclisiran, while demonstrating substantial small-study exaggeration and healthy-user bias in observational statin literature.
Answers are grounded in this paper and cite their sources.
Small-study bias inflates cholesterol risks and statin harms; confirms modest effects from large randomized evidence and cautions against observational cohorts.
In plain words: High cholesterol goes with heart disease, newer drugs cut LDL a lot, and the dramatic statin and risk figures shrink in careful studies. 1. Risks. High LDL or total cholesterol is linked with cardiovascular disease (ratio 1.58 (95% CI 1.26 to 1.98), prediction interval 0.53 to 4.72, k = 25), hypertension and other cardiometabolic conditions (1.58 (95% CI 1.37 to 1.81)) and kidney disease (1.36 (95% CI 1.16 to 1.59)), all three Firm; coronary disease, stroke, liver disease and cancer are Provisional; death (1.05 (95% CI 0.91 to 1.20)), diabetes and dementia are not supported. 2. What small studies exaggerate. For high cholesterol the ratio rises by a factor of 4.0 (95% CI 1.5 to 10.5) per unit of standard error; the least precise third of studies pools to 1.80 against 1.19 for the most precise third, robust to clustering and to omitting any family. Adjustment (1.12), publication from 2021 (1.22), East Asia (0.88) and ratio type (1.28) do not explain ratios within family (null). 3. Lowering LDL. PCSK9 inhibitors and inclisiran lower LDL by a median of 50% in reported falls (k = 42); diets and supplements by about 10 mg/dL (0.25 mmol/L) in meta-analyses, where the less precise half is 3.3 times larger than the more precise half (-10.1 against -3.1 mg/dL). Statin LDL falls are too thin (k = 3) to rank. 4. Statin benefit, two kinds of evidence. Cohorts give 0.70 (95% CI 0.63 to 0.77) for all-cause mortality (k = 22, Firm) against a reader-confirmed meta-analysis median of 0.86 (k = 5); the gap fits confounding by indication and healthy-user bias, not a larger drug effect. 5. Side-effect claims. New-onset diabetes 1.50 (95% CI 1.22 to 1.84) (Provisional, failing the precise-half test; blinded-trial odds ratio about 1.09) and muscle symptoms 1.49 (95% CI 1.00 to 2.23) (not supported); harms are small where the evidence is best and larger in cohorts that mention them. 6. News against search. Validated news openings on statin side effects fell from 4.3% to 0.8% (change -3.4 points, 95% CI -4.2 to -2.7) while searches for statin side effects reached 1.97 times their 2019 level (weather control 1.13); detrended, deseasonalised news and search correlate at 0.21 for cholesterol and are not stable over time. 7. Context. The research layer holds 22,795 core studies (2017 to 2025), of which 9% have drug treatment as their focus; the search index for cholesterol averaged 78 in 2025 to 2026; 12,044 news openings were read. 8. Method. Ratio rows were re-read from quotations by a strict parser (280 of 3,368 candidates removed) and pooled within outcome family (DerSimonian-Laird, prediction intervals); every field and flag used passed a blind second reading at 70% agreement or better; failed fields (therapy estimates, per cent LDL falls, age) were restricted to confirmed rows or dropped. Research preprint, not peer reviewed. The ratios are associations reported in the cited studies and are not medical advice. Author: Narendra Kumar (ORCID 0009-0001-7468-6100). This paper was not produced entirely by AI; the blind second readers used for validation are AI readers, named in the paper. Also deposited at: https://doi.org/10.5281/zenodo.24124588; https://doi.org/10.6084/m9.figshare.34977631
No takes yet. Share an insight, caveat, or question.
Narendra Kumar (2026) conducted a meta-analysis in High LDL or total cholesterol. High LDL or total cholesterol and lipid-lowering therapies (PCSK9 inhibitors, inclisiran, statins, diet, and supplements) was evaluated on Cardiovascular disease associated with high LDL or total cholesterol (Ratio 1.58, 95% CI 1.26-1.98). High LDL or total cholesterol was linked with cardiovascular disease, while PCSK9 inhibitors and inclisiran lowered LDL by a median of 50%.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: